ArriVent BioPharma, Inc. AVBP Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s total liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported total liabilities of $25.32M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s total liabilities increased by 95.4% year-over-year, from $12.95M to $25.32M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total liabilities has grown at a 48.3% compound annual growth rate (CAGR), from $11.8M to $25.95M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.